CombiMatrix Corporation to Release Fourth Quarter and Year-End Financial Results on February 27, 2013

CombiMatrix Corporation to Release Fourth Quarter and Year-End Financial
Results on February 27, 2013

IRVINE, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX) announced today that it will release its fourth quarter and
year-end 2012 financial results on Wednesday, February 27, 2013. Results will
be released prior to trading on that day.

A conference call has also been scheduled regarding CombiMatrix Corporation's
fourth quarter and year-end 2012 financial results. The presentation and Q&A
session will start at 8:00 a.m. Pacific Time (11:00 a.m. Eastern) on February
27, 2013.

To attend the presentation by phone, dial 1-888-395-3227 for domestic callers
and 1-719-325-2215 for direct-dial or international callers. To listen to the
call via CombiMatrix's website, go to www.combimatrix.com in the
Investor/Events section (http://investor.combimatrix.com/events.cfm).

A replay of the presentation will be available following the presentation,
either via the CombiMatrix website Investor/Events section
(http://investor.combimatrix.com/events.cfm) or by dialing 1-877-870-5176 for
domestic callers or 1-858-384-5517 for direct-dial international callers. When
prompted, enter playback pin number 3824098.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets. The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies. CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals. Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624

         Investor Relations Contact:
         Matthew H. Clawson
         Partner, Allen & Caron, Inc.
         Tel (949) 474-4300
         matt@allencaron.com